NorthStrive Biosciences Advances EL-32 Manufacturing for Muscle Preservation in GLP-1 Therapy Patients
核心洞察
NorthStrive Biosciences (搜索) successfully transferred EL-32 Working Cell Bank to a U.S. fermentation facility to initiate manufacturing optimization for its dual myostatin (搜索)-targeting probiotic therapeutic.
EL-32 is designed to preserve lean muscle mass in patients undergoing GLP-1 receptor agonist (搜索) weight loss therapy by targeting both myostatin (搜索) and activin-A (搜索) pathways through oral delivery.
The company filed 10 U.S. patent applications expanding EL-22 and EL-32 technologies into animal health markets, covering muscle growth enhancement in livestock, aquaculture, and poultry.
NorthStrive Biosciences (搜索) has reached a significant manufacturing milestone for its engineered probiotic therapeutic EL-32, successfully transferring the Working Cell Bank to a U.S.-based fermentation facility to begin production optimization. The dual-action therapeutic targets muscle preservation in patients receiving GLP-1 receptor agonist (搜索) weight loss treatments.
Manufacturing Scale-Up Initiative
The transfer of EL-32's Working Cell Bank to a third-party precision fermentation facility marks the initiation of a comprehensive manufacturing optimization program. The facility will lead upstream and downstream process development using data-driven optimization strategies to improve yield, consistency, and manufacturability.
NorthStrive Biosciences (搜索) is collaborating with Modulant Biosciences LLC (搜索), which holds an exclusive license for EL-32-derived products in non-human animal health applications. This partnership leverages shared manufacturing and process development insights while maintaining NorthStrive's exclusive rights to human therapeutic applications.
The manufacturing optimization aims to establish a robust process foundation supporting investigational new drug (IND)-enabling activities and future good manufacturing practices (GMP) manufacturing for clinical and commercial development.
Dual-Target Mechanism of Action
EL-32 represents a differentiated approach to addressing muscle loss during weight reduction therapy. The engineered probiotic therapeutic expresses both myostatin (搜索) and activin-A (搜索) antigens, two key biological regulators of muscle development and metabolic function.
By targeting both the myostatin (搜索) and activin-A (搜索) pathways through an oral, gut-mediated delivery mechanism, EL-32 offers a novel solution for preserving lean muscle mass and addressing metabolic dysfunction (搜索) in patients undergoing GLP-1 receptor agonist (搜索) weight loss therapy.
Expanding Patent Portfolio
NorthStrive Biosciences (搜索) has filed ten new U.S. patent applications expanding its EL-22 and EL-32 technologies into animal health and agricultural markets. The applications cover multiple farmed animal categories, including livestock, aquaculture, and poultry.
The patent applications address muscle growth enhancement in livestock (U.S. Application Nos. 19/541,209 for EL-22 and 19/540,888 for EL-32), designed to encourage animals to grow new muscle tissue and increase muscle weight return per animal. Additional applications cover emissions reduction in livestock and aquaculture, as well as muscle development in poultry.
Strategic Development Approach
The collaboration between NorthStrive Biosciences (搜索) and Modulant Biosciences reflects a dual-track development strategy intended to maximize the commercial potential of the EL-32 platform across both human therapeutic and animal health markets. This parallel approach allows both companies to leverage shared manufacturing insights while pursuing distinct market applications.
NorthStrive Biosciences (搜索), a wholly owned subsidiary of PMGC Holdings Inc. (搜索) (NASDAQ: ELAB), focuses on developing cutting-edge therapeutic solutions, with EL-32 representing a key asset in addressing the clinical challenge of muscle preservation during weight loss interventions.